Method for separating and determining dotenorad key intermediate and related compounds thereof by HPLC (High Performance Liquid Chromatography)
The HPLC method for separating and determining key intermediates and related compounds of dotenorolac solves the problem of separation difficulties in existing technologies, achieves efficient and accurate quality control, and ensures the purity and quality of dotenorolac raw material.
Patent Information
- Application Number
- CN202511139465.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-08-14
- Publication Date
- 2025-10-31
AI Technical Summary
In the existing technology, key intermediates and related impurity compounds of dotenorolac are difficult to separate effectively, which affects the quality control of dotenorolac active pharmaceutical ingredient, and there is a lack of efficient and accurate analytical methods.
By employing HPLC with specific diluent and mobile phase combinations, combined with gradient elution and principal component self-comparison, we can achieve efficient separation and quantitative analysis of key intermediates and related compounds of dotenoroxetine.
This study achieved highly sensitive, well-separated, and stable analysis of key intermediates and related impurity compounds in dotenoramide, ensuring quality control of the dotenoramide synthesis route and the quality of the final product.
Smart Images

Figure CN120870393A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of analytical chemistry, and more specifically, to a method for separating and determining key intermediates of dotenoroxetine and related compounds by HPLC. Background Technology
[0002] Gout is an acute inflammatory disease caused by the deposition of urate crystals in the joints and surrounding soft tissues. Its main symptoms include recurrent joint pain and swelling, and in severe cases, it can lead to joint deformities and functional impairment. Gout not only significantly reduces patients' quality of life but can also trigger a series of serious complications, such as cardiovascular disease and kidney disease, seriously threatening their lives. Hyperuricemia, as an important biochemical basis of gout, is a common metabolic disease. When uric acid production is excessive or excretion is reduced, it leads to elevated blood uric acid levels, which in turn triggers gout and a series of other diseases.
[0003] Dotinurad is a selective inhibitor of urate reabsorption transporter 1 (URAT1). By selectively inhibiting this transporter, it suppresses urate reabsorption and lowers serum uric acid levels. Clinically, it is used to treat gout and hyperuricemia in adults. Urate transporter 1 belongs to the organic anion transporter family and is an important renal urate transporter, primarily involved in the reabsorption of uric acid in the proximal convoluted tubule. URAT1 is an important target for the treatment of chronic gout. URAT1 inhibitors can inhibit uric acid reabsorption by suppressing URAT1 protein activity, thereby promoting uric acid excretion and lowering serum uric acid levels.
[0004] Currently, the quality standards for dotenorazole are not included in the United States Pharmacopeia, the European Pharmacopeia, the Japanese Pharmacopeia, or the Chinese Pharmacopeia, and there are relatively few reports on analytical methods related to its key intermediates. Generally speaking, the total impurity content of a drug should be less than 1.0%, and the content of a single impurity should be less than 0.1%. Impurities or related substances generated or introduced during the preparation of dotenorazole must be strictly controlled, whether in the active pharmaceutical ingredient or the finished product.
[0005] (3,5-Dichloro-4-methoxyphenyl)(1,1-benzo[d]thiazolyl-3(2H)-yl) methyl ketone is a key intermediate in dotenorazole. Quality control of this compound plays an important role in the preparation of high-quality dotenorazole active pharmaceutical ingredient. Therefore, developing an efficient and accurate analytical method for quality analysis of this key intermediate is of great significance for the subsequent preparation of high-purity dotenorazole products.
[0006] In the preparation of the key intermediate (3,5-dichloro-4-methoxyphenyl)(1,1-benzo[d]thiazol-3(2H)-yl) methyl ketone, some impurities are inevitably introduced, including the compound 3,5-dichloro-4-methoxybenzoic acid remaining in the starting material, the compound benzo[d]thiazol-3(2H)-yl(3,5-dichloro-4-methoxyphenyl) methyl ketone caused by the residue of intermediate products, the intermediate compound (3,5-dichloro-4-methoxyphenyl)(1-benzo[d]thiazol-3(2H)-yl) methyl ketone formed by the incomplete oxidation of intermediate products, and the impurity compound (3,5-dichloro-4-methoxyphenyl)(1,1-benzo[d]thiazol-3(2H)-yl) methyl ketone formed by potential processes. The study explores how to avoid the influence of these compounds on the main components, improve the purity of the main components, and control the synthetic route or reaction process of the key intermediates of dotenorolac by analyzing the content of these compounds. This is of paramount importance. It also addresses the compounds formed by the dechlorination of key intermediates, such as (3-chloro-4-methoxyphenyl)(1,1-benzo[d]thiazol-3(2H)-yl) ketone, (3-chloro-4-methoxyphenyl)(1,1-benzo[d]thiazol-3(2H)-yl) ketone, and (3,5-dichloro-4-hydroxyphenyl)(1,1-benzo[d]thiazol-4-yl) ketone, which is generated by demethylation of potential processes. Summary of the Invention
[0007] To address the aforementioned technical problems, the present invention aims to provide an HPLC method for separating and determining key intermediates and related compounds of dotenoradine. The method of the present invention can effectively separate key intermediates and related impurity compounds of dotenoradine, and exhibits high sensitivity and resolution, good repeatability and robustness, simple operation, and stable and reliable results.
[0008] The objective of this invention is achieved through the following technical solution: In a first aspect, the present invention provides an HPLC method for separating and determining key intermediates and related compounds of dotenorazole, wherein the key intermediates of dotenorazole include (3,5-dichloro-4-methoxyphenyl)(1,1-benzo[d]thiazolyl) ketone, and the related compounds include one or more of compounds A, B, C, D, E, and F, as shown in the table below:
[0009] (3,5-Dichloro-4-methoxyphenyl)(1,1-benzo[d]thiazolyl) methyl ketone is a key intermediate in the synthesis of dotenorazole, and its chemical formula is C 15 H 11Cl2NO4S, with the structural formula shown in Formula (I), is referred to in this invention as "Compound of Formula I" or "Key Intermediate of Dotenorazole": (I).
[0010] As some specific embodiments of the present invention, the method includes the following steps: S1. Preparation of test solution: Dissolve the test sample in diluent to prepare a solution containing 0.5±0.05mg per ml. S2. Preparation of control solution: Take an appropriate amount of the test solution and dilute it with diluent to prepare a solution containing 2.5±0.05μg per ml, which is used as the control solution; S3. Preparation of sensitivity solution: Take an appropriate amount of the control solution and dilute it with diluent to prepare a solution containing 0.25±0.05μg per ml, which is used as the sensitivity solution; S4. Inject the sensitivity solution prepared in step S3 into a sample and perform high performance liquid chromatography analysis. Record the chromatogram and determine the sensitivity of the analytical method for key intermediates of dotenorazole. Then, take the test solution from step S1 and the control solution from step S2 respectively, perform high performance liquid chromatography analysis, record the chromatogram, and calculate the content of each relevant compound in the test sample according to the main component self-comparison method.
[0011] The relevant compounds corresponding to each chromatographic peak on the chromatogram are determined based on the chromatographic peaks obtained by individually injecting and detecting the reference standards of each relevant compound.
[0012] As some specific embodiments of the present invention, the diluent is a mixed solution of acetonitrile and water with a volume ratio of 55:45 to 65:35.
[0013] As some specific embodiments of the present invention, in step S4, when performing high performance liquid chromatography analysis, the mobile phase used to elute the sample includes mobile phase A and mobile phase B, wherein mobile phase A includes an aqueous solution of phosphoric acid and mobile phase B includes an organic solvent.
[0014] Furthermore, the volume percentage of phosphoric acid in the phosphoric acid aqueous solution is 0.05-0.5%; preferably 0.1%. And / or, the organic solvent is selected from one or more of acetonitrile, ethanol and methanol; preferably acetonitrile.
[0015] As some specific embodiments of the present invention, the elution is gradient elution, and the elution gradient includes:
[0016] Preferably, the elution gradient is:
[0017] As some specific embodiments of the present invention, when performing gradient elution, the flow rate of the mobile phase is 0.8-1.2 mL / min; preferably 1.0 mL / min.
[0018] As some specific embodiments of the present invention, in step S4, when performing high performance liquid chromatography analysis, the chromatographic column used is filled with phenylsilane-bonded silica gel, and the particle size of the filler is 2-5 μm, preferably 5 μm; And / or, the column temperature of the chromatographic column is 25-35℃, preferably 30℃; And / or, the detection wavelength is 250±5nm, preferably 254nm.
[0019] As some specific embodiments of the present invention, in step S4, the formula for calculating the content of each relevant compound in the test sample using the principal component self-comparison method is as follows: The calculation formula is as follows: Related compounds (%) = ×100% In the formula: The peak area of the relevant compounds of the key intermediate of dotenorazine in the test solution; The peak area of the main peak in the control solution; F is the correction factor; V represents the dilution factor of the control solution.
[0020] The aforementioned correction factor F is determined based on the slope of the linear equations for the key intermediate of dotenoradine and each related compound in the linear validation results. Specifically, it is obtained by dividing the slope of the linear equation for the key intermediate of dotenoradine by the slope of the linear equation for each related compound.
[0021] In a second aspect, the present invention provides the application of the method as described in any of the preceding claims in the detection of key intermediates of dotenorolac and their impurities, wherein the impurities include one or more of compounds A, B, C, D, E, and F.
[0022] The reagent composition provided by this invention for solid-liquid separation determination of key intermediates and related compounds of dotenorolac can effectively separate key intermediates and related impurity compounds of dotenorolac, which is of great significance for achieving quality control of key intermediates and dotenorolac.
[0023] Compared with the prior art, the present invention has the following beneficial effects: 1) This invention provides an HPLC method for separating and determining key intermediates of dotenoradine and related compounds. The method of this invention can effectively separate key intermediates of dotenoradine and related impurity compounds. The method has high sensitivity and resolution, good repeatability and robustness, simple operation, and stable and reliable results.
[0024] 2) Research revealed that compounds B, C, D, E, and F have structures very similar to the key intermediates in the preparation of dotenoradine. If this step is not controlled, these compounds will be difficult to remove if introduced into subsequent dotenoradine synthesis. Therefore, strict monitoring of each impurity compound is necessary in this step. The method of this invention separates the key dotenoradine intermediates from related impurity compounds, and reverse quality control of the synthetic route is achieved by analyzing the content of related compounds, thereby further reducing the formation of these compounds. Therefore, the analysis and research of the key dotenoradine intermediates and related impurity compounds in this invention plays a crucial role in controlling the synthetic reaction and improving its quality, directly affecting the quality of the finished dotenoradine product. This is of paramount importance for achieving quality control of the key dotenoradine intermediates and dotenoradine itself. Attached Figure Description
[0025] Other features, objects, and advantages of the present invention will become more apparent from the following detailed description of non-limiting embodiments with reference to the accompanying drawings: Figure 1 This is a chromatogram of the system suitability solution used in the specificity verification of Example 3; Figure 2 The chromatogram of the system suitability solution for Comparative Example 1; Figure 3 The chromatogram is for the system suitability solution of Comparative Example 2. Detailed Implementation
[0026] The present invention will now be described in detail with reference to specific embodiments. These embodiments will help those skilled in the art to further understand the present invention, but do not limit the invention in any way. It should be noted that those skilled in the art can make several modifications and improvements without departing from the concept of the present invention. These all fall within the protection scope of the present invention. Experimental methods not specified with specific conditions in the embodiments are generally performed under conventional conditions. The key intermediate of dotenorazole in the embodiments refers to compound of formula I.
[0027] Example 1 Patent application CN120398788A discloses a synthetic route for dotenorazole, which uses 2-aminothiophenol as a starting material, reacts with formaldehyde in a condensation reaction to obtain benzothiazoline, then undergoes an amidation reaction with 3',5-dichloro-4-methoxybenzoyl chloride, followed by oxidation and demethylation reactions to prepare dotenorazole. In this synthetic route, the key intermediate (3,5-dichloro-4-methoxyphenyl)(1,1-benzo[d]thiazo-3(2H)-yl) methyl ketone, namely the compound of formula I shown below, is obtained before the demethylation reaction to obtain dotenorazole. (I).
[0028] This process generates other related compounds, including one or more of the following: compound A due to residues of starting materials, compound B due to residues of intermediate products, intermediate compound C formed from incomplete oxidation of intermediate products, compound D formed by potential processes, compound E formed from the dechlorination of compound (I), and compound F generated from the demethylation of potential processes.
[0029] The relevant compounds A and F are shown in Table 1 below: Table 1 List of relevant compounds
[0030] The structural formulas of compound AF in Table 1 are shown in formulas II-VII below: (II) (III) (IV) (V) (VI) (VII).
[0031] Example 2 2.1 Solution Preparation Take an appropriate amount of the test sample (mainly composed of the key intermediate of dotenorolac), accurately weigh it, dissolve it in acetonitrile-water (volume ratio 60:40) and quantitatively dilute it to prepare a solution containing approximately 0.5 mg per ml, as the test solution; accurately measure an appropriate amount of the test solution, dilute it with acetonitrile-water (volume ratio 60:40) to prepare a solution containing approximately 2.5 μg per ml, as the control solution; accurately measure an appropriate amount of the control solution, dilute it with acetonitrile-water (volume ratio 60:40) to prepare a solution containing approximately 0.25 μg per ml, as the sensitivity solution.
[0032] 2.2 Detection Method (1) Accurately measure the sensitivity solution and inject it into the sample. Perform high performance liquid chromatography analysis, record the chromatogram, and determine the sensitivity. Then, accurately measure the test solution and the control solution, and perform high-performance liquid chromatography analysis on them respectively, and record the chromatograms.
[0033] The relevant compounds corresponding to each chromatographic peak on the chromatograms of the test solution and the control solution are determined based on the chromatographic peaks obtained from the individual injection and detection of each relevant compound reference standard.
[0034] (2) The chromatographic conditions for HPLC are as follows: Chromatographic column: Kromasil 100-5 phenyl (250 mm × 4.6 mm, 5 μm), mobile phase A: 0.1% (v / v) phosphoric acid aqueous solution, mobile phase B: acetonitrile, gradient elution was performed, and the gradient elution settings are shown in Table 2 below: Table 2 Elution gradient table
[0035] Flow rate: 1 ml / min, column temperature: 30℃, detection wavelength: 254 nm, injection volume: 10 µl.
[0036] (3) Calculate the content of each relevant compound in the test sample using the principal component self-comparison method with correction factors. The calculation formula is as follows: Related compounds (%) = ×100% In the formula: The peak area of the relevant compounds of the key intermediate of dotenorazine in the test solution; The peak area of the main peak in the control solution; F is the correction factor; V represents the dilution factor of the control solution.
[0037] The correction factor F is determined based on the slope of the linear equations for the key intermediate of dotenorazole and each related compound in the linear validation results. Specifically, it is obtained by dividing the slope of the linear equation for the key intermediate of dotenorazole by the slope of the linear equation for each related compound.
[0038] Example 3 The key intermediates and related compound AF reference standards used in the following validations are shown below: (1) Key intermediate of dotenorazole: (3,5-dichloro-4-methoxyphenyl)(1,1-benzo[d]thiazolyl) methyl ketone, CAS number 1285573-44-5, purchased from QCS Standard Material R&D Center, product code RM-D152112.
[0039] (2) Compound A: 3,5-dichloro-4-methoxybenzoic acid, CAS number 37908-97-7.
[0040] (3) Compound B: benzo[d]thiazol-3(2H)-yl(3,5-dichloro-4-methoxyphenyl) methyl ketone, CAS number 1285573-42-3.
[0041] (4) Compound C: (3,5-dichloro-4-methoxyphenyl)(1-benzo[d]thiazol-3(2H)-yl) methyl ketone, CAS number 1285573-47-8.
[0042] (5) Compound D: (3,5-dichloro-4-methoxyphenyl)(1,1-dioxide-2,3-dihydro-4H-benzo[b][1,4]thiazin-4-yl) methyl ketone, purchased from QCS Standard Material R&D Center, product code RM-D152146.
[0043] (6) Compound E: (3-chloro-4-methoxyphenyl)(1,1-benzo[d]thiazol-3(2H)-yl) methyl ketone, purchased from QCS Standard Material R&D Center, product code RM-D152136.
[0044] (7) Compound F: (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxide-2,3-dihydro-4H-benzo[b][1,4]thiazin-4-yl) methyl ketone, CAS number 888730-55-0, purchased from QCS Standard Material R&D Center, product code RM-D152123.
[0045] The following verifications were performed: 3.1 Specificity Take appropriate amounts of reference standards of compounds A, B, C, D, E, and F, accurately weigh them, and place them in different volumetric flasks. Dissolve and dilute each flask with acetonitrile-water (volume ratio 60:40) to prepare a solution containing 500 μg per ml, which will be used as the stock solution of the relevant compound reference standards.
[0046] Take an appropriate amount of the key intermediate of dotenorazole, add an appropriate amount of stock solution of each relevant compound reference standard, dissolve and dilute with acetonitrile-water (volume ratio 60:40) to prepare a solution containing approximately 0.5 mg of compound I and approximately 5 μg of each relevant compound per 1 ml, as a system suitability solution.
[0047] Accurately measure 10 μl of the system suitability solution and the stock solutions of each relevant compound reference standard, inject them into the liquid chromatograph, perform HPLC, and record the chromatograms. The results for the system suitability solution are shown in the appendix. Figure 1Based on the chromatograms of the relevant compound reference stock solutions, the chromatographic peaks of each relevant compound on the chromatogram of the system suitability solution were determined. The elution order of the system suitability solution was as follows: compound F (retention time Rt 14.464), compound A (retention time Rt 15.009), compound C (retention time Rt 18.182), compound E (retention time Rt 21.892), compound D (retention time Rt 22.722), compound I (retention time Rt 26.232), and compound B (retention time Rt 31.049). In the system suitability solution, the resolution between the key intermediate of dotenoradine and the adjacent relevant compound peaks was greater than 1.5, with a retention time Rt of 26.232.
[0048] 3.2 Repeatability Take appropriate amounts of key intermediates and related compound reference standards of dotenoroxetine, dissolve and dilute them in acetonitrile-water (60:40 v / v) to prepare a solution containing approximately 0.5 mg of compound I, approximately 2.5 μg of compound A, approximately 2.5 μg of compound B, approximately 0.5 μg of compound C, approximately 2.5 μg of compound D, approximately 2.5 μg of compound E, and approximately 2.5 μg of compound F per 1 ml, as the spiked test solution; accurately measure 1 ml of the spiked test solution and place it in a 200 ml volumetric flask, dilute it with acetonitrile-water (60:40 v / v) to prepare a solution containing approximately 2.5 μg of compound I per 1 ml, as the control solution. Accurately measure the above spiked test solution and control solution and inject them, recording the chromatograms. Calculate the RSD (relative standard deviation) of the contents of each related compound in the six spiked test solutions using the principal component self-comparison method with correction factors, and the results are shown in Table 3. The RSDs of the contents of each relevant compound detected in the six spiked test solutions were all less than 10.0%, which meets the requirements of high performance liquid chromatography for the detection of related substances.
[0049] Table 3 Repeatability test results
[0050] 3.3 Linear Take appropriate amounts of reference standards for key intermediates of dotenorolac and related compounds, dissolve and dilute them in acetonitrile-water (60:40 v / v) to prepare a solution containing approximately 5 μg of compound I, 5 μg of compound A, 5 μg of compound B, 5 μg of compound C, 1 μg of compound D, 5 μg of compound E, and 5 μg of compound F per 1 ml, as a linear stock solution. Measure 2.5 ml, 4 ml, 5 ml, and 7.5 ml of the stock solution into 10 ml volumetric flasks, respectively, and dilute to the mark with acetonitrile-water (60:40 v / v), and mix well. Separately, take the limit of quantitation solution and the linear stock solution as the linear test solution. Perform linear regression on peak area against concentration to obtain the linear equation (as shown in Table 4). Key intermediates of dotenorolac and related compounds exhibit good linearity within the linear range. Based on the linearity determination results, the correction factor for each related compound is obtained by dividing the slope of the linear equation of the principal component I compound by the slope of the linear equation of each related compound (as shown in Table 5).
[0051] Table 4 Linearity Measurement Results
[0052] Table 5 Correction Factor Table
[0053] 3.4 Limits of Detection and Limits of Quantification Take appropriate amounts of reference standards for key intermediates and related compounds of dotenoradine, place them in suitable volumetric flasks, dissolve and dilute to the mark with solvent, and shake well to prepare solutions with a concentration of approximately 0.2 μg / ml for each related compound and compound of formula I, as the limit of quantitation (S / N ≥ 10). Take 3 ml of the limit of quantitation solution, place it in a 10 ml volumetric flask, dissolve and dilute to the mark with solvent, and shake well to prepare solutions with a concentration of approximately 0.06 μg / ml for each related compound and compound of formula I, as the limit of detection (S / N ≥ 3). The results of the limits of quantitation and limits of detection for key intermediates and related compounds of dotenoradine are shown in Table 6.
[0054] Table 6 Results of Limit of Quantitation and Limit of Detection
[0055] 3.5 Accuracy Take appropriate amounts of reference standards for compounds A, B, C, D, E, and F, dissolve and dilute them separately with acetonitrile-water (60:40 v / v) to prepare solutions containing approximately 500 μg of compound A, 500 μg of compound B, 100 μg of compound C, 500 μg of compound D, 500 μg of compound E, and 500 μg of compound F per 1 ml, as stock solutions for each relevant compound. Accurately measure 2 ml of each relevant compound stock solution and place it in a 20 ml volumetric flask, dilute to the mark with acetonitrile-water (60:40 v / v), and shake well to prepare a mixed reference stock solution. Accurately weigh approximately 10 mg of dotenoradine intermediate, place it in a 20 ml volumetric flask, add the mixed reference stock solution, place it in the above-mentioned volumetric flasks, dilute to the mark with acetonitrile-water (60:40 v / v), and shake well to prepare the recovery test solution, in 6 parallel applications. The recoveries and RSDs of each relevant compound were calculated using the principal component self-comparison method with correction factors, and the results are shown in Table 7 below. The results indicate that the recoveries of each relevant compound at various concentrations were between 80.0% and 120.0%, and the RSDs were all less than 10.0%, meeting the requirements for the detection of related substances by high-performance liquid chromatography.
[0056] Table 7 Accuracy Test Results
[0057] 3.6 Conclusion: Under the above chromatographic conditions, key intermediates of dotenoradine and related compounds can be completely separated. This method is highly specific, accurate, sensitive, reproducible, and system-compatible, meeting the technical requirements of drug quality research standards, and the results obtained are stable and reliable.
[0058] Comparative Example 1 1. Chromatographic conditions: Chromatographic column: ACE EXCEL 3 C18-PFP-3 (250 mm × 4.6 mm, 3 μm); mobile phase A: 10 mmol / L potassium dihydrogen phosphate buffer (pH adjusted to 2.0 with phosphoric acid); mobile phase B: acetonitrile; gradient elution was performed, and the gradient elution settings are shown in Table 8 below. Table 8 Elution Gradient Table
[0059] Flow rate: 1.0 ml / min, column temperature: 30℃, detection wavelength: 254 nm, injection volume: 10 µl.
[0060] 2. Method: Accurately weigh appropriate amounts of the key intermediate of dotenoradine and compounds A, C, and F, place them in the same volumetric flask, dissolve and dilute with 60% acetonitrile to prepare a solution containing approximately 0.5 mg of compound I, approximately 0.1 mg of compound C, and approximately 5 μg of compound F per ml. This solution is used as the system suitability solution. Accurately inject 10 μl into the liquid chromatograph and record the chromatogram. The chromatogram of the system suitability solution is shown in the appendix. Figure 2 .
[0061] 3. Conclusion: Under these chromatographic conditions, the resolution of compound F (retention time Rt 14.899) with known compound A (retention time 15.247) is 1.1, which is less than the requirement of the Chinese Pharmacopoeia (the resolution should be greater than 1.5). Compound F and compound A did not achieve baseline separation, which affected the quantitative results and qualitative judgment of compounds F and A.
[0062] Comparative Example 2 1. Chromatographic conditions: Chromatographic column: Kromasil 100-5 phenyl (250 mm × 4.6 mm, 5 μm), mobile phase A: 0.1% phosphoric acid aqueous solution, mobile phase B: acetonitrile, gradient elution was performed, and the gradient elution settings are shown in Table 9 below: Table 9 Elution Gradient Table
[0063] Flow rate: 1.0 ml / min, column temperature: 30℃, detection wavelength: 254 nm, injection volume: 10 µl.
[0064] 2. The method is the same as Comparative Example 1. The system suitability solution chromatogram is attached. Figure 3 .
[0065] 3. Conclusion: Under these chromatographic conditions, the resolution of compound F (retention time Rt 14.595) with known compound A (retention time 14.911) is 1.2, which is less than the requirement of the Chinese Pharmacopoeia (the resolution should be greater than 1.5). Compound F and compound A did not achieve baseline separation, which affected the quantitative results and qualitative judgment of compounds F and A.
[0066] The specific embodiments of the present invention have been described above. It should be understood that the present invention is not limited to the specific embodiments described above, and those skilled in the art can make various modifications or variations within the scope of the claims, which do not affect the essence of the present invention.
Claims
1. A method for separating and determining key intermediates and related compounds of dotenorolac by HPLC, characterized in that, The key intermediate of dotenorazole includes (3,5-dichloro-4-methoxyphenyl)(1,1-benzo[d]thiazolyl) methyl ketone, and the related compounds include one or more of compounds A, B, C, D, E, and F, wherein compound AF specifically refers to: 。 2. The method according to claim 1, characterized in that, The method includes the following steps: S1. Preparation of test solution: Dissolve the test sample in diluent to prepare a solution containing 0.5±0.05mg per ml. S2. Preparation of control solution: Take an appropriate amount of the test solution and dilute it with diluent to prepare a solution containing 2.5±0.05μg per ml, which is used as the control solution; S3. Preparation of sensitivity solution: Take an appropriate amount of the control solution and dilute it with diluent to prepare a solution containing 0.25±0.05μg per ml, which is used as the sensitivity solution; S4. Inject the sensitivity solution prepared in step S3 into a sample and perform high performance liquid chromatography analysis. Record the chromatogram and determine the sensitivity of the analytical method for key intermediates of dotenorazole. Then, take the test solution from step S1 and the control solution from step S2 respectively, perform high performance liquid chromatography analysis, record the chromatogram, and calculate the content of each relevant compound in the test sample according to the main component self-comparison method.
3. The method according to claim 2, characterized in that, The diluent is a mixed solution of acetonitrile and water with a volume ratio of 55:45 to 65:
35.
4. According to the method of claim 2, in step S4, when performing high performance liquid chromatography analysis, the mobile phase used to elute the sample includes mobile phase A and mobile phase B, wherein mobile phase A includes an aqueous solution of phosphoric acid and mobile phase B includes an organic solvent.
5. The method according to claim 4, characterized in that, The volume percentage of phosphoric acid in the phosphoric acid aqueous solution is 0.05-0.5%; And / or, the organic solvent is selected from one or more of acetonitrile, ethanol and methanol.
6. The method according to claim 4, characterized in that, The elution is gradient elution, and the elution gradient includes: 。 7. The method according to claim 6, characterized in that, When performing gradient elution, the flow rate of the mobile phase is 0.8-1.2 mL / min.
8. The method according to claim 2, characterized in that, In step S4, when performing high performance liquid chromatography analysis, the chromatographic column used is filled with phenylsilane-bonded silica gel, and the particle size of the filler is 2-5 μm. And / or, the column temperature of the chromatographic column is 25-35℃; And / or, the detection wavelength is 250±5nm.
9. The method according to claim 2, characterized in that, In step S4, the formula for calculating the content of each relevant compound in the test sample using the principal component self-comparison method is as follows: Related compounds (%) = ×100%; In the formula: The peak area of the relevant compounds of the key intermediate of dotenorazine in the test solution; The peak area of the main peak in the control solution; F is the correction factor; V represents the dilution factor of the control solution.
10. The application of the method according to any one of claims 1-9 in the detection of dotenoroxetine key intermediates and their impurities, said impurities comprising one or more of compounds A, B, C, D, E, and F.
Citation Information
Patent Citations
Preparation method of dotenorad key intermediate
CN120398788A
